Why is Balaxi Pharma falling/rising?

As of 19-Sep, Balaxi Pharmaceuticals Ltd is currently priced at 46.77, reflecting an increase of 0.73 or 1.59%. The stock has outperformed its sector today by 1.74%, although it is trading above its 5-day and 20-day moving averages but below its longer-term moving averages (50-day, 100-day, and 200-day). Over the past week, the stock has gained 2.79%, yet it has seen a significant decline of 57.25% over the past year, indicating a consistent underperformance against the benchmark. The company's fundamentals show strong long-term potential with an average Return on Equity (ROE) of 30.97% and a favorable valuation at a Price to Book Value of 1.1. However, the stock has also faced negative pressures, including a substantial drop in profits by 49.8% and a decrease in institutional investor participation by 7.16%, which may contribute to the stock's volatility.
In the broader market context, Balaxi Pharmaceuticals has outperformed the Sensex by 2.79% over the past week, while the benchmark has only gained 0.85%. Despite this short-term outperformance, the stock's long-term trajectory remains concerning, with a year-to-date decline of 35.32% compared to the Sensex's increase of 7.11%. The overall market sentiment appears to be cautious, especially given the stock's significant underperformance over the last three years and the recent negative financial results, which may lead to continued skepticism among investors.